Android app on Google Play

Brean Murray Carret & Co. Starts Synergy Pharmaceuticals (SGYP) at Buy; Second to Start, But Looking To Finish First

March 29, 2012 8:10 AM EDT Send to a Friend
Get Alerts SGYP Hot Sheet
Price: $3.90 +3.17%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 4 | New: 7
Trade SGYP Now!
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy. PT $13.00.

Analyst, Jonathan Aschoff, said, "A key investment catalyst is the Q212 release of Phase 2/3 plecanatide results in CIC, a significant de-risking event. Another important positive catalyst is the 2Q12 PDUFA date for competing drug linaclotide, which we expect to result in a approval that formally validates the mechanism, driving SGYP shares higher."

For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.

Shares of Synergy Pharmaceuticals closed at $3.99 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment